• Completed

NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM

Updated: Apr 25


NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma



RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide and dexamethasone together with bortezomib may kill more cancer cells.


PURPOSE: This phase II trial is studying giving cyclophosphamide and dexamethasone together with bortezomib to see how well it works in treating patients with newly diagnosed multiple myeloma.


Sponsors and Collaborators

Mayo Clinic

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier: NCT00609167


Official Title: A Phase II Trial of Cyclophosphamide, Bortezomib and Dexamethasone (CYBOR-D) in Patients With Newly Diagnosed Active Multiple Myeloma

First Posted: February 6, 2008


Click here to see details on ClinicalTrials.gov

 

Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Cyclophosphamide : National Cancer Institute

Cyclophosphamide : MedlinePlus Drug Information

Cyclophosphamide IV : MedlinePlus Drug Information

 

Drug: bortezomib

Drug: cyclophosphamide

Drug: dexamethasone

 

Leukemia; 2009

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

In conclusion, CyBorD produces a rapid and profound response in patients with newly diagnosed MM with manageable toxicity.

Click here for details

 

Blood; 2010

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma


Click here for details


 

Br J Haematol; 2014

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma


https://pubmed.ncbi.nlm.nih.gov/24974945/

 

Locations


United States, Arizona

Mayo Clinic in Arizona


Canada, Ontario

Princess Margaret Hospital



Posts Archive